첫 페이지 News 본문

On December 7th, Abbey and Cerevel Therapeutics announced a final agreement - Abbey will acquire Cerevel Therapeutics and its neuroscience pipeline. Cerevel's pipeline consists of multiple clinical stages and preclinical candidate drugs developed to treat diseases such as schizophrenia, Parkinson's disease (PD), and mood disorders.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

tengxiao 新手上路
  • Follow

    0

  • Following

    0

  • Articles

    0